Cargando…
Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model
BACKGROUND: Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) hold promise as a disease modifying treatment in osteoarthritis (OA). Obesity, and its associated inflammation, contribute to OA development and metabolic OA represents a specific and significant group...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210425/ https://www.ncbi.nlm.nih.gov/pubmed/37226203 http://dx.doi.org/10.1186/s13287-023-03368-7 |
_version_ | 1785047063687331840 |
---|---|
author | Warmink, Kelly Rios, Jaqueline L. Varderidou-Minasian, Suzy Torres-Torrillas, Marta van Valkengoed, Devin R. Versteeg, Sabine Eijkelkamp, Niels Weinans, Harrie Korthagen, Nicoline M. Lorenowicz, Magdalena J. |
author_facet | Warmink, Kelly Rios, Jaqueline L. Varderidou-Minasian, Suzy Torres-Torrillas, Marta van Valkengoed, Devin R. Versteeg, Sabine Eijkelkamp, Niels Weinans, Harrie Korthagen, Nicoline M. Lorenowicz, Magdalena J. |
author_sort | Warmink, Kelly |
collection | PubMed |
description | BACKGROUND: Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) hold promise as a disease modifying treatment in osteoarthritis (OA). Obesity, and its associated inflammation, contribute to OA development and metabolic OA represents a specific and significant group of the OA patient population. Given their immunomodulatory properties, MSC and MSC-EVs are especially interesting for this group of patients as a therapeutic option. Here, we were the first to compare the therapeutic efficacy of MSCs and MSC-EVs in a mild OA model taking these metabolic aspects into consideration. METHODS: Male Wistar-Han rats (Crl:WI(Han) (n = 36) were fed a high fat diet for 24 weeks, with unilateral induction of OA by groove surgery after 12 weeks. Eight days after surgery rats were randomized in three treatment groups receiving MSCs, MSC-EVs or vehicle injection. Pain-associated behavior, joint degeneration, and local and systemic inflammation were measured. RESULTS: We demonstrated that despite not having a significant therapeutic effect, MSC-EV treatment results in lower cartilage degeneration, less pain behaviour, osteophytosis and joint inflammation, than MSC treatment. Suggesting that MSC-EVs could be a more promising therapeutic strategy than MSCs in this mild metabolic OA model. CONCLUSION: In summary, we find that MSC treatment has negative effects on the joint in metabolic mild OA. This is an essential finding for the significant group of patients with metabolic OA phenotype, and might help to understand why clinical translation of MSC treatment shows varying therapeutic efficacy thus far. Our results also suggest that MSC-EV-based treatment might be a promising option for these patients, however MSC-EV therapeutic efficacy will need improvement. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03368-7. |
format | Online Article Text |
id | pubmed-10210425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102104252023-05-26 Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model Warmink, Kelly Rios, Jaqueline L. Varderidou-Minasian, Suzy Torres-Torrillas, Marta van Valkengoed, Devin R. Versteeg, Sabine Eijkelkamp, Niels Weinans, Harrie Korthagen, Nicoline M. Lorenowicz, Magdalena J. Stem Cell Res Ther Research BACKGROUND: Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) hold promise as a disease modifying treatment in osteoarthritis (OA). Obesity, and its associated inflammation, contribute to OA development and metabolic OA represents a specific and significant group of the OA patient population. Given their immunomodulatory properties, MSC and MSC-EVs are especially interesting for this group of patients as a therapeutic option. Here, we were the first to compare the therapeutic efficacy of MSCs and MSC-EVs in a mild OA model taking these metabolic aspects into consideration. METHODS: Male Wistar-Han rats (Crl:WI(Han) (n = 36) were fed a high fat diet for 24 weeks, with unilateral induction of OA by groove surgery after 12 weeks. Eight days after surgery rats were randomized in three treatment groups receiving MSCs, MSC-EVs or vehicle injection. Pain-associated behavior, joint degeneration, and local and systemic inflammation were measured. RESULTS: We demonstrated that despite not having a significant therapeutic effect, MSC-EV treatment results in lower cartilage degeneration, less pain behaviour, osteophytosis and joint inflammation, than MSC treatment. Suggesting that MSC-EVs could be a more promising therapeutic strategy than MSCs in this mild metabolic OA model. CONCLUSION: In summary, we find that MSC treatment has negative effects on the joint in metabolic mild OA. This is an essential finding for the significant group of patients with metabolic OA phenotype, and might help to understand why clinical translation of MSC treatment shows varying therapeutic efficacy thus far. Our results also suggest that MSC-EV-based treatment might be a promising option for these patients, however MSC-EV therapeutic efficacy will need improvement. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03368-7. BioMed Central 2023-05-24 /pmc/articles/PMC10210425/ /pubmed/37226203 http://dx.doi.org/10.1186/s13287-023-03368-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Warmink, Kelly Rios, Jaqueline L. Varderidou-Minasian, Suzy Torres-Torrillas, Marta van Valkengoed, Devin R. Versteeg, Sabine Eijkelkamp, Niels Weinans, Harrie Korthagen, Nicoline M. Lorenowicz, Magdalena J. Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model |
title | Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model |
title_full | Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model |
title_fullStr | Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model |
title_full_unstemmed | Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model |
title_short | Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model |
title_sort | mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than msc-based treatment in a mild metabolic osteoarthritis model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210425/ https://www.ncbi.nlm.nih.gov/pubmed/37226203 http://dx.doi.org/10.1186/s13287-023-03368-7 |
work_keys_str_mv | AT warminkkelly mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT riosjaquelinel mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT varderidouminasiansuzy mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT torrestorrillasmarta mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT vanvalkengoeddevinr mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT versteegsabine mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT eijkelkampniels mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT weinansharrie mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT korthagennicolinem mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel AT lorenowiczmagdalenaj mesenchymalstemstromalcellsderivedextracellularvesiclesasapotentiallymorebeneficialtherapeuticstrategythanmscbasedtreatmentinamildmetabolicosteoarthritismodel |